Citations

Showing 10 of 108094 citations.

A Swollen Supraglottis
Syal, Amit , Karle, William E. , Chen, Longwen

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | October 6, 2022 | Volume: 148 | Issue: 11 | Pages: 1075

10.1001/jamaoto.2022.2878 | PMID 36201228 Get It

A woman in her late 20s presented with difficulty phonating and singing for the past 15 months and no improvement from prior treatment with steroids and antibiotics for chronic laryngitis. What is your diagnosis?
A Preliminary Investigation into the Factor Structure of Two Psychological Flexibility Measures in a Sample of Community-Dwelling Older Adults
Adamowicz, Jenna L. , Thomas, Emily B.K. , Hsu, Ti , Denburg, Natalie L. , Roche, Anne I.

Mayo Clinic

Clinical Gerontologist | October 6, 2022 | Volume: 46 | Issue: 4 | Pages: 561-573

10.1080/07317115.2022.2131496 | PMID 36201007 Get It

Two FTD-ALS genes converge on the endosomal pathway to induce TDP-43 pathology and degeneration
Shao, Wei , Todd, Tiffany W. , Wu, Yanwei , Jones, Caroline Y. , Tong, Jimei, Jansen‐West, Karen , Daughrity, Lillian M. , Park, Jinyoung , Koike, Yuka , Kurti, Aishe, Yue, Mei, Castanedes‐Casey, Monica , Rosso, Giulia del, Dunmore, Judith A. , Alepuz, Desiree Zanetti , Oskarsson, Björn , Cook, Casey , Prudencio, Mercedes , Fryer, John Denis , Zhang, Yong‐Jie , Petrucelli, Leonard , Del Rosso, Giulia, Zanetti Alepuz, Desiree, Dickson, Dennis W , Cook, Casey N , Prudencio, Mercedes , Gendron, Tania F , Zhang, Yong-Jie , Petrucelli, Leonard , Oskarsson, Björn , Shao, Wei , Koike, Yuka , Dickson, Dennis W. , Gendron, Tania F.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 94-99

10.1126/science.abq7860 | PMID 36201573 Get It

Frontotemporal dementia and amyotrophic lateral sclerosis (FTD-ALS) are associated with both a repeat expansion in the C9orf72 gene and mutations in the TANK-binding kinase 1 ( TBK1 ) gene. We found that TBK1 is phosphorylated in response to C9orf72 poly(Gly-Ala) [poly(GA)] aggregation and sequestered into inclusions, which leads to a loss of TBK1 activity and contributes to neurodegeneration. When we reduced TBK1 activity using a TBK1-R228H (Arg 228 →His) mutation in mice, poly(GA)-induced phenotypes were exacerbated. These phenotypes included an increase in TAR DNA binding protein 43 (TDP-43) pathology and the accumulation of defective endosomes in poly(GA)-positive neurons. Inhibiting the endosomal pathway induced TDP-43 aggregation, which highlights the importance of this pathway and TBK1 activity in pathogenesis. This interplay between C9orf72 , TBK1 , and TDP-43 connects three different facets of FTD-ALS into one coherent pathway.
A noncoding single-nucleotide polymorphism at 8q24 drives IDH1 -mutant glioma formation
Yanchus, Connor , Drucker, Kristen , Kollmeyer, Thomas M. , Tsai, Ricky , Winick‐Ng, Warren , Liang, Minggao , Malik, Ahmad , Pawling, Judy , Lorenzo, Silvana B. De, Ali, Asma, Decker, Paul A. , Kosel, Matt, Panda, Arijit , Al‐Zahrani, Khalid N. , Jiang, Lingyan , Browning, Jared , Lowden, Christopher , Hernández, J. Javier , Gosio, Jessica , Loganathan, Sampath K. , Berman, Jacob M. , Trcka, Daniel , Michealraj, Kulandaimanuvel Antony , Fortin, Jérôme, Carson, Brittany B. , Hollingsworth, Ethan W. , Jacinto, Sandra , Mazrooei, Parisa, Zhou, Lily , Elia, Andrew , Lupien, Mathieu , Murphy, Daniel J. , Wang, Liguo , Abyzov, Alexej , Dennis, James W. , Maass, Philipp G. , Wrensch, Margaret , Mak, Tak W. , Visel, Axel , Wrana, Jeffrey L. , Zadeh, Gelareh , Eckel‐Passow, Jeanette E. , Attisano, Liliana , Pombo, Ana , Kvon, Evgeny Z. , Jenkins, Robert B. , Schramek, Daniel , Drucker, Kristen L , De Lorenzo, Silvana B, Kosel, Matt L, Browning, Jared W L , Lowden, Chris , Hernandez, J Javier , Ahmed, Musaddeque , Loganathan, Sampath Kumar , Berman, Jacob , Trcka, Daniel , Hollingsworth, Ethan W , Elia, Andrew , Lupien, Mathieu , He, Housheng Hansen , Wang, Liguo , Abyzov, Alexej , Dennis, James W , Maass, Philipp G , Wilson, Michael D , Wrensch, Margaret , Mak, Tak , Pennacchio, Len A , Dickel, Diane E , Visel, Axel , Wrana, Jeffrey , Dirks, Peter , Eckel-Passow, Jeanette E , Attisano, Liliana , Pombo, Ana , Ida, Cristiane M , Kvon, Evgeny Z , Jenkins, RB , Schramek, Daniel , Kollmeyer, Thomas , Murphy, Daniel J , Decker, Paul A. , Kosel, Matthew , Geuenich, Michael J. , Ahmed, Musaddeque , He, Housheng Hansen , Campbell, Kieran R. , Wilson, Michael D. , Lachance, Daniel Honore , Wiencke, John K. , Taylor, Michael D. , Ida, Cristiane M.

Mayo Clinic

Science | October 6, 2022 | Volume: 378 | Issue: 6615 | Pages: 68-78

10.1126/science.abj2890 | PMID 36201590 Get It

Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single-nucleotide polymorphism rs55705857, which confers a sixfold greater risk of isocitrate dehydrogenase ( IDH) –mutant low-grade glioma (LGG). We reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. Mutating the orthologous mouse rs55705857 locus accelerated tumor development in an Idh1 R132H -driven LGG mouse model from 472 to 172 days and increased penetrance from 30% to 75%. Our work reveals mechanisms of the heritable predisposition to lethal glioma in ~40% of LGG patients.
A Note on Monkeypox for Our Patients With Inflammatory Bowel Disease
Lutz, Megan , Caldera, Freddy , Caldera, Freddy , Hayney, Mary S. , Farraye, Francis A.

Mayo Clinic

Inflammatory Bowel Diseases | October 6, 2022 | Volume: 29 | Issue: 1 | Pages: 179-180

10.1093/ibd/izac214 | PMID 36200852 Get It

Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
Razonable, Raymund R. , Tulledge‐Scheitel, Sidna M. , Hanson, Sara N. , Arndt, Richard , Speicher, Leigh L. , Seville, Teresa A, Larsen, Jennifer J., Ganesh, Ravindra , O’Horo, John C. , Arndt, Richard F, Razonable, Raymund R , Ganesh, Ravindra , O'Horo, John C

Mayo Clinic

Open Forum Infectious Diseases | October 6, 2022 | Volume: 9 | Issue: 10 | Pages: No page available

10.1093/ofid/ofac411 | PMID 36213724 Get It

Abstract Background Antispike monoclonal antibodies are recommended for early treatment of high-risk persons with mild to moderate coronavirus disease 2019 (COVID-19). However, clinical outcomes of their use during the severe acute respiratory syndrome coronavirus 2 Omicron wave are limited. Methods This is a descriptive retrospective study of high-risk adult patients who received treatment with sotrovimab (January 1–March 20, 2022) or bebtelovimab (March 21–April 30, 2022). The primary outcome was the proportion of patients who progressed to severe outcome within 30 days after receiving antispike-neutralizing monoclonal antibody infusion. Results A total of 3872 high-risk patients (median age, 62.7 years; 41.1% male) with mild to moderate COVID-19 received sotrovimab (n = 2182) or bebtelovimab (n = 1690). Among sotrovimab-treated patients, the most common comorbidities were an immunosuppressed condition (46.7%), hypertension (38.2%), and diabetes (21.2%). The rates of severe outcome, intensive care unit (ICU) admission, and mortality were 2.2%, 1.0%, and 0.4%, respectively, after sotrovimab infusion. Among bebtelovimab-treated patients, the most common comorbidities were hypertension (42.7%), diabetes (17.1%), and an immunosuppressed condition (17.0%). The rates of severe disease, ICU admission, and mortality were 1.3%, 0.5%, and 0.2%, respectively, after bebtelovimab infusion. Older age, immunosuppressed status, and several comorbidities were associated with severe disease progression, while COVID-19 vaccination was associated with lower risk. No anaphylaxis was reported during monoclonal antibody infusion. Conclusions This real-world analysis of a large cohort of high-risk patients demonstrates low rates of severe disease after treatment with sotrovimab during the era dominated by Omicron B.1.1.529 and after treatment with bebtelovimab during the era dominated by BA.2 and Omicron subvariants.
Ustekinumab-Associated Posterior Reversible Encephalopathy Syndrome in a Patient With Crohn's Disease
Jordan, Ariel , Kinnucan, Jami

Mayo Clinic

ACG Case Reports Journal | October 6, 2022 | Volume: 9 | Issue: 10 | Pages: e00867

10.14309/crj.0000000000000867 | PMID 36212237 Get It

ABSTRACT Ustekinumab is a common biologic therapy for the treatment of inflammatory bowel disease. Posterior reversible encephalopathy syndrome (PRES) is an uncommon condition consisting of a constellation of neurologic findings and characteristic findings on imaging. The association between ustekinumab and PRES is not well defined. We present a case of PRES in a patient with Crohn's disease on ustekinumab and a brief review of the literature. Clinicians should be aware of this rare complication with high morbidity in patients with inflammatory bowel disease on ustekinumab and be able to recognize clinical symptoms.
Endoscopic Ultrasound-Guided Gastrojejunostomy for Superior Mesenteric Artery Syndrome Secondary to Rapid Weight Loss
Mahmoud, Tala , Akiki, Karl, Law, Ryan , Law, Ryan J, Storm, Andrew C. , Akiki, Karl

Mayo Clinic

ACG Case Reports Journal | October 6, 2022 | Volume: 9 | Issue: 10 | Pages: e00868

10.14309/crj.0000000000000868 | PMID 36212239 Get It

ABSTRACT A 19-year-old man diagnosed with diffuse large B-cell lymphoma undergoing chemotherapy presented for recurrent emesis and weight loss. Imaging studies of the abdomen demonstrated features of superior mesenteric artery syndrome. The patient deferred conservative treatment options and was deemed not to be a surgical candidate. Endoscopic ultrasound-guided gastroenterostomy using a lumen-apposing metal stent was performed to bypass the obstruction. Subsequently, the patient's oral intake and weight significantly improved. The stent was removed 6 months after placement with resolution of superior mesenteric artery syndrome symptoms.
Posterolateral Corner Reconstruction Using Double Femoral Fixation With Adjustable Loop Cortical Suspension and Interference Screw
Kennedy, Nicholas I. , Therrien, Érik , Marx, Robert G. , Levy, Bruce A. , Stuart, Michael J.

Mayo Clinic

Video Journal of Sports Medicine | October 6, 2022 | Volume: 2 | Issue: 5 | Pages: No page available

10.1177/26350254221114890 | PMID 40309451 Get It

Background: The posterolateral corner (PLC) of the knee is a complex anatomic region of the knee comprising the popliteus tendon, the popliteofibular ligament (PFL), and the fibular collateral ligament (FCL). Treatment of PLC injuries is based on the degree of varus and rotational instability on preoperative examination and is recommended in grade 3 injuries. 1,6 Technique Description: The key concept of this new surgical technique is to use adjustable loop cortical suspensory fixation implants for initial femoral fixation of the popliteus and the FCL grafts. This allows for individual tensioning of the grafts prior to definitive fixation with an interference screw. An anatomic fibular tunnel is initially created, followed by popliteus and FCL anatomic femoral socket drilling. A TightRope RT implant is attached to the popliteus end of the graft and secured through a bone tunnel on the medial femoral cortex initially. The popliteus end of the graft is then pulled into the femoral socket before tunneling the graft through the fibular tunnel. A second TightRope RT implant is secured to the FCL end of the graft before securing it to the medial femoral cortex through a bone tunnel and pulling the graft into the drilled femoral socket. An interference screw is first used to secure the graft at the fibular tunnel. The knee is then taken to 60° where the TightRope device is used to remove residual creep and optimize final tensioning prior to final fixation with interference screw in femoral socket. With the knee at 30° of flexion, neutral rotation, and slight valgus, the same steps are repeated for FCL graft. A posterolateral capsular shift is completed for additional stability. Results: Residual posterolateral corner instability or failure after reconstruction surgery has been reported in 6% to 9.4% of surgical reconstruction case. 2,3,5 The use of cortical suspensory devices in PLC reconstructions allows independent dialing of optimal graft tension for both the popliteus and FCL reconstruction before final interference screw fixation, therefore presumably limiting any residual creep and allowing for a double femoral fixation of the graft. Discussion: We describe a novel technique for posterolateral corner reconstruction which allows for optimal and individual tensioning of the structures of the posterolateral corner. Given the technique still uses well-described and validated graft choices and anatomic landmarks for reconstruction, we expect this new technique to allow for similar if not improved outcomes when compared with current gold standard. 4
There are Considerable Inconsistencies Among Minimum Clinically Important Differences in TKA: A Systematic Review
Deckey, David G. , Verhey, Jens T. , Gerhart, Coltin R. B. , Christopher, Zachary K. , Spangehl, Mark J. , Clarke, Henry D. , Bingham, Joshua S.

Mayo Clinic

Clinical Orthopaedics & Related Research | October 6, 2022 | Volume: 481 | Issue: 1 | Pages: 63-80

10.1097/corr.0000000000002440 | PMID 36200846 Get It

Abstract Background Patient-reported outcome measures (PROMs) are frequently used to assess the impact of total knee arthroplasty (TKA) on patients. However, mere statistical comparison of PROMs is not sufficient to assess the value of TKA to the patient, especially given the risk profile of arthroplasty. Evaluation of treatment effect sizes is important to support the use of an intervention; this is often quantified with the minimum clinically important difference (MCID). MCIDs are unique to specific PROMs, as they vary by calculation methodology and study population. Therefore, a systematic review of calculated MCID values, their respective ranges, and assessment of their applications is important to guide and encourage their use as a critical measure of effect size in TKA outcomes research. Questions/purposes In this systematic review of MCID calculations and reporting in primary TKA, we asked: (1) What are the most frequently reported PROM MCIDs and their reported ranges in TKA? (2) What proportion of studies report distribution- versus anchor-based MCID values? (3) What are the most common methods by which these MCID values are derived for anchor-based values? (4) What are the most common derivation methods for distribution-based values? (5) How do the reported medians and corresponding interquartile ranges (IQR) compare between calculation methods for each PROM? Methods Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic review was conducted using the PubMed, EMBASE, and MEDLINE databases from inception through March 2022 for TKA articles reporting an MCID value for any PROMs. Two independent reviewers screened articles for eligibility, including any article that calculated new MCID values for PROMs after primary TKA, and extracted these data for analysis. Overall, 576 articles were identified, 38 of which were included in the final analysis. These studies had a total of 710,128 patients with a median age of 67.7 years and median BMI of 30.9 kg/m 2 . Women made up more than 50% of patients in most studies, and the median follow-up period was 17 months (range 0.25 to 72 months). The overall risk of bias was assessed as moderate using the Jadad criteria for one randomized controlled trial (3 of 5 ideal global score) and the modified Methodological Index for Non-randomized Studies criteria for comparative studies (mean 17.2 ± 1.8) and noncomparative studies (mean 9.6 ± 1.3). There were 49 unique PROMs for which 233 MCIDs were reported. Calculated values were classified as anchor-based, distribution-based, or not reported. MCID values for each PROM, MCID calculation method, number of patients, and study demographics were extracted from each study. Anchor-based and distribution-based MCIDs were compared for each unique PROM using a Wilcoxon rank sum test given non-normal distribution of values. Results The WOMAC Function and Pain subscores were the most frequently reported MCID value, comprising 9% (22 of 233) and 9% (22 of 233), respectively. The composite Oxford Knee Score (OKS) was the next most frequently reported (9% [21 of 233]), followed by the WOMAC composite score (6% [13 of 233]). The median anchor-based values for WOMAC Function and Pain subscores were 23 (IQR 16 to 33) and 25 (IQR 14 to 31), while the median distribution-based values were 11 (IQR 10.8 to 11) and 22 (IQR 17 to 23), respectively. The median anchor-based MCID value for the OKS was 6 (IQR 4 to 7), while the distribution-based value was 7 (IQR 5 to 10). Thirty-nine percent (15 of 38) used an anchor-based method to calculate a new MCID, while 32% (12 of 38) used a distribution-based technique. Twenty-nine percent of studies (11 of 38) calculated MCID values using both methods. For studies reporting an anchor-based calculation method, a question assessing patient satisfaction, pain relief, or quality of life along a five-point Likert scale was the most commonly used anchor (40% [16 of 40]), followed by a receiver operating characteristic curve estimation (25% [10 of 40]). For studies using distribution-based calculations, all articles used a measure of study population variance in their derivation of the MCID, with the most common method reported as one-half the standard deviation of the difference between preoperative and postoperative PROM scores (45% [14 of 31]). Most reported median MCID values (15 of 19) did not differ by calculation method for each unique PROM (p > 0.05) apart from the WOMAC Function component score and the Knee Injury and Osteoarthritis Outcome Score Pain and Activities of Daily Living subscores. Conclusion Despite variability of MCIDs for each PROM, there is consistency in the methodology by which MCID values have been derived in published studies. Additionally, there is a consensus about MCID values regardless of calculation method across most of the PROMs we evaluated. Clinical Relevance Given their importance to treatment selection and patient safety, authors and journals should report MCID values with greater consistency. We recommend using a 7-point increase as the MCID for the OKS, consistent with the median reported anchor-based value derived from several high-quality studies with large patient groups that used anchor-based approaches for MCID calculation, which we believe are most appropriate for most applications in clinical research. Likewise, we recommend using a 10-point to 15-point increase for the MCID of composite WOMAC, as the median value was 12 (IQR 10 to 17) with no difference between calculation methods. We recommend use of median reported values for WOMAC function and pain subscores: 21 (IQR 15 to 33) and 23 (IQR 13 to 29), respectively.